Guilford Gliadel NDA to be filed in February for brain tumors for first- and second-line use.
Executive Summary
GUILFORD LIKELY TO FILE GLIADEL NDA FOR TREATMENT OF GLIOMA IN FEBRUARY, VP-Business Development Nicholas Landekic stated at Hambrecht & Quist's annual health care conference Jan. 9 in San Francisco. "We originally planned to submit the NDA in December but decided to delay the submission briefly in order to broaden our proposed indication for the inclusion of the European clinical trial data, which would allow us to apply for an indication for all patients undergoing surgery for malignant gliomas," he said.